Palatin Technologies, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Palatin Technologies, Inc. - overview
Established
1986
Location
-, NJ, US
Primary Industry
Biotechnology
About
Palatin Technologies, Inc. is a US-based biotechnology company focused on developing innovative therapeutics for inflammatory and autoimmune diseases, particularly ocular conditions, through advanced therapeutic solutions. Palatin Technologies, Inc. was founded in 1986 and is headquartered in New Jersey, USA.
The company specializes in developing novel therapeutics aimed at addressing inflammatory and autoimmune conditions. John Prendergast founded the company to advance therapeutic innovation in the biotech field. Palatin completed a successful IPO in March 2011, raising a total of USD 23 mn. Palatin Technologies specializes in developing novel therapeutics aimed at addressing inflammatory and autoimmune conditions, with a strong focus on ocular diseases.
Their core product, VYLEESI® (bremelanotide injection), engages the melanocortin system, a natural pathway in the body, to mitigate harmful inflammation and promote tissue healing. This innovative approach enhances patient experience and provides physicians with effective treatment options for patients suffering from chronic inflammation. The company markets its products primarily in the United States, where there is a significant demand for treatments for ocular conditions and other inflammatory diseases. In 2022, Palatin Technologies generated revenue of USD 1,468,457.
The company’s revenue is derived from direct sales of its flagship product, VYLEESI®, through partnerships with healthcare providers and institutions. The pricing model reflects its specialized nature, targeting patients with unmet medical needs in inflammatory and autoimmune disease segments. Revenue streams depend on prescription volumes and market adoption rates of their therapies. Palatin Technologies is focused on expanding its portfolio by developing new therapeutic products aimed at inflammatory and autoimmune diseases, with specific plans to launch new products in upcoming years.
The company aims to penetrate additional markets, particularly in Europe and Asia, by 2025. Recent funding, including USD 10 mn from its latest Venture Debt round, will support these initiatives, facilitating research and development as well as market entry strategies.
Current Investors
New Jersey Economic Development Authority, Horizon Technology Finance Corporation, QVT funds
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceuticals
Website
www.palatin.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Palatin Technologies, Inc. - financials
| Fiscal Year Ended | Jun 30, 2011 | Jun 30, 2012 | Jun 30, 2013 | Jun 30, 2014 | Jun 30, 2015 | Jun 30, 2016 | Jun 30, 2017 | Jun 30, 2018 | Jun 30, 2019 | Jun 30, 2020 | Jun 30, 2021 | Jun 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 1,475,457 | 73,736 | 10,361 | - | 12,951,730 | - | 44,723,827 | 67,134,758 | 60,300,476 | - | - | - |
| % Revenue Growth (YoY) | - | (95.0%) | (85.9%) | (100.0%) | - | (100.0%) | - | 50.1% | (10.2%) | - | - | - |
| EBITDA (USD) | (12,515,203) | (17,835,839) | (15,474,681) | (15,675,746) | (17,168,567) | (49,207,083) | (10,536,443) | 25,983,134 | 35,802,955 | - | - | - |
| Operating Income (USD) | (13,653,386) | (18,785,381) | (15,585,160) | (15,787,652) | (17,286,157) | (49,250,135) | (10,569,494) | 25,926,565 | 35,744,320 | - | - | - |
| Operating Margin | (925.4%) | (25476.5%) | (150421.4%) | - | (133.5%) | - | (23.6%) | 38.6% | 59.3% | - | - | - |
| % EBITDA Margin | (848.2%) | (24188.8%) | (149355.1%) | - | (132.6%) | - | (23.6%) | 38.7% | 59.4% | - | - | - |
| NET Income (USD) | (12,815,929) | (17,253,178) | (20,862,174) | (13,928,294) | (17,665,563) | (51,712,936) | (13,331,533) | 24,702,714 | 35,773,027 | - | - | - |
| % Net Margin | (868.6%) | (23398.6%) | (201352.9%) | - | (136.4%) | - | (29.8%) | 36.8% | 59.3% | - | - | - |
Palatin Technologies, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Vyleesi | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.